TY - JOUR
T1 - The Use of Test-negative Controls to Monitor Vaccine Effectiveness
T2 - A Systematic Review of Methodology
AU - Chua, Huiying
AU - Feng, Shuo
AU - Lewnard, Joseph A.
AU - Sullivan, Sheena G.
AU - Blyth, Christopher C.
AU - Lipsitch, Marc
AU - Cowling, Benjamin J.
N1 - Funding Information:
This work was supported by a commissioned grant from the Health and Medical Research Fund of the Food and Health Bureau of Hong Kong, and the Research Grants Council of the Hong Kong Special Administrative Region (project no. T11-705/14N). M.L. and B.J.C. are supported by the Harvard Center for Communicable Disease Dynamics from the National Institute of General Medical Sciences (grant no. U54 GM088558). The WHO Collaborating Centre for Reference and Research on Influenza is supported by the Australian Government Department of Health. The funding bodies had no role in study design, data collection and analysis, preparation of the manuscript, or the decision to publish.
Publisher Copyright:
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2020/1
Y1 - 2020/1
N2 - Background: The test-negative design is an increasingly popular approach for estimating vaccine effectiveness (VE) due to its efficiency. This review aims to examine published test-negative design studies of VE and to explore similarities and differences in methodological choices for different diseases and vaccines. Methods: We conducted a systematic search on PubMed, Web of Science, and Medline, for studies reporting the effectiveness of any vaccines using a test-negative design. We screened titles and abstracts and reviewed full texts to identify relevant articles. We created a standardized form for each included article to extract information on the pathogen of interest, vaccine(s) being evaluated, study setting, clinical case definition, choices of cases and controls, and statistical approaches used to estimate VE. Results: We identified a total of 348 articles, including studies on VE against influenza virus (n = 253), rotavirus (n = 48), pneumococcus (n = 24), and nine other pathogens. Clinical case definitions used to enroll patients were similar by pathogens of interest but the sets of symptoms that defined them varied substantially. Controls could be those testing negative for the pathogen of interest, those testing positive for nonvaccine type of the pathogen of interest, or a subset of those testing positive for alternative pathogens. Most studies controlled for age, calendar time, and comorbidities. Conclusions: Our review highlights similarities and differences in the application of the test-negative design that deserve further examination. If vaccination reduces disease severity in breakthrough infections, particular care must be taken in interpreting vaccine effectiveness estimates from test-negative design studies.
AB - Background: The test-negative design is an increasingly popular approach for estimating vaccine effectiveness (VE) due to its efficiency. This review aims to examine published test-negative design studies of VE and to explore similarities and differences in methodological choices for different diseases and vaccines. Methods: We conducted a systematic search on PubMed, Web of Science, and Medline, for studies reporting the effectiveness of any vaccines using a test-negative design. We screened titles and abstracts and reviewed full texts to identify relevant articles. We created a standardized form for each included article to extract information on the pathogen of interest, vaccine(s) being evaluated, study setting, clinical case definition, choices of cases and controls, and statistical approaches used to estimate VE. Results: We identified a total of 348 articles, including studies on VE against influenza virus (n = 253), rotavirus (n = 48), pneumococcus (n = 24), and nine other pathogens. Clinical case definitions used to enroll patients were similar by pathogens of interest but the sets of symptoms that defined them varied substantially. Controls could be those testing negative for the pathogen of interest, those testing positive for nonvaccine type of the pathogen of interest, or a subset of those testing positive for alternative pathogens. Most studies controlled for age, calendar time, and comorbidities. Conclusions: Our review highlights similarities and differences in the application of the test-negative design that deserve further examination. If vaccination reduces disease severity in breakthrough infections, particular care must be taken in interpreting vaccine effectiveness estimates from test-negative design studies.
UR - https://www.scopus.com/pages/publications/85075958920
U2 - 10.1097/EDE.0000000000001116
DO - 10.1097/EDE.0000000000001116
M3 - Review Article
C2 - 31609860
AN - SCOPUS:85075958920
SN - 1044-3983
VL - 31
SP - 43
EP - 64
JO - Epidemiology
JF - Epidemiology
IS - 1
ER -